{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-034523","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.035623+00:00","generated_at":"2026-05-15T09:09:01.231608+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Armata Pharma Q4 net loss $124.3M on $105.8M non-cash fair value loss; going concern noted","bullets":["Q4 2025 grant revenue $1.1M vs $1.2M YoY; R&D expenses $6.1M vs $8.5M YoY.","Net loss $124.3M ($3.42/sh) vs net income $2.6M ($0.07/sh) in Q4 2024; includes $105.8M non-cash fair value loss on convertible loan.","Recognized $5.4M impairment expense on vacated Marina del Rey office lease.","Cash & equivalents $14.1M as of Dec 31 2025; amended debt agreements extending maturities to June 2027.","Audited 2025 financials include going concern qualification; ~36.6M shares outstanding as of Mar 18 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-034523","json":"https://secwatch.observer/filing/0001104659-26-034523.json","markdown":"https://secwatch.observer/filing/0001104659-26-034523.md","text":"https://secwatch.observer/filing/0001104659-26-034523.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465926034523/0001104659-26-034523-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465926034523/armp-20260325x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:09:01.231608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad124d25096a6b8d3f52ac7f00d743a29d65323c","claim":"Armata Pharmaceuticals, Inc. reported the three months and full fiscal year ended December 31, 2025 results: net income $124.3 million, EPS $(3.42) per share.","evidence_excerpt":"Armata Pharmaceuticals, Inc. announced its financial results for the three months and full fiscal year ended December 31, 2025, in the press release furnished hereto as Exhibit 99.1.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926034523/0001104659-26-034523-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months and full fiscal year ended December 31, 2025"},{"label":"Net income","value":"$124.3 million"},{"label":"EPS","value":"$(3.42) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}